Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Peter Störz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0132-5128; OpenAlex author ID A5064581175; NIH RePORTER profile ID 8508292. Sources: funder_awards.

Their work

Papers
25 (first author 8, last author 8)
Trials
0
Grants
7
Labs led
1
Collaborators
22
Papers, trials and grants by year

2008: 1 grant · 2009: none · 2010: none · 2011: none · 2012: none · 2013: 2 papers · 2014: 1 grant · 2015: 3 papers · 2016: 3 papers · 2017: 4 papers · 2018: none · 2019: 2 papers · 2020: 2 papers, 1 grant · 2021: 1 grant · 2022: 1 paper · 2023: 1 paper, 1 grant · 2024: 4 papers · 2025: 2 papers, 1 grant · 2026: 1 paper, 1 grant

Papers 25

  1. Early induction of the Rho-GEF ECT2 drives MEK/ERK oncogenic signaling in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-026-03860-3↗
  2. A vaccination strategy to prevent coxsackie virus B3-induced development of pancreatic cancer. Last author DOI 10.1172/jci.insight.192629↗
  3. Downregulation of Sod2 increases atypical flat lesions and dysplasia to advance pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12943-025-02518-0↗
  4. Protein kinase D1 - A targetable mediator of pancreatic cancer development. First author DOI 10.1016/j.bbamcr.2023.119646↗
  5. Coxsackievirus and adenovirus receptor expression facilitates enteroviral infections to drive the development of pancreatic cancer. Last author DOI 10.1038/s41467-024-55043-x↗
  6. Earliest Metabolic Changes Associated with the Initiation of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-0874↗
  7. Macrophage-induced reactive oxygen species in the initiation of pancreatic cancer: a mini-review. First author DOI 10.3389/fimmu.2024.1278807↗
  8. Roles of differently polarized macrophages in the initiation and progressionof pancreatic cancer. Co-author DOI 10.3389/fimmu.2023.1237711↗
  9. Ym1+ macrophages orchestrate fibrosis, lesion growth, and progression during development of murine pancreatic cancer. Last author DOI 10.1016/j.isci.2022.104327↗
  10. Carcinogenesis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2020.02.059↗
  11. Early detection and imaging strategies to reveal and target developing pancreatic cancer Last author DOI 10.1080/14737140.2020.1720654↗
  12. Sangivamycin and its derivatives inhibit Haspin-Histone H3-survivin signaling and induce pancreatic cancer cell death. Last author DOI 10.1038/s41598-019-53223-0↗
  13. Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma. First author DOI 10.1080/14737140.2019.1622417↗
  14. Acinar cell plasticity and development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nrgastro.2017.12↗
  15. Targeting reactive oxygen species in development and progression of pancreatic cancer. First author DOI 10.1080/14737140.2017.1261017↗
  16. KRas, ROS and the initiation of pancreatic cancer. Co-author DOI 10.1080/21541248.2016.1192714↗
  17. Mitochondrial and Oxidative Stress-Mediated Activation of Protein Kinase D1 and Its Importance in Pancreatic Cancer. First author DOI 10.3389/fonc.2017.00041↗
  18. The PRKD1 promoter is a target of the KRas-NF-κB pathway in pancreatic cancer. Last author DOI 10.1038/srep33758↗
  19. A bright future for protein kinase D1 as a drug target to prevent or treat pancreatic cancer. First author DOI 10.1080/23723556.2015.1035477↗
  20. NFATc4 Regulates Sox9 Gene Expression in Acinar Cell Plasticity and Pancreatic Cancer Initiation. Co-author DOI 10.1155/2016/5272498↗
  21. Targeting protein kinase C subtypes in pancreatic cancer. Co-author DOI 10.1586/14737140.2015.1003810↗
  22. Protein kinase D enzymes: novel kinase targets in pancreatic cancer. First author DOI 10.1586/17474124.2015.1069706↗
  23. Inflammatory macrophages in pancreatic acinar cell metaplasia and initiation of pancreatic cancer. First author DOI 10.18632/oncoscience.151↗
  24. Downregulation of TRAF2 mediates NIK-induced pancreatic cancer cell proliferation and tumorigenicity. Last author DOI 10.1371/journal.pone.0053676↗
  25. Targeting the alternative NF-κB pathway in pancreatic cancer: a new direction for therapy? Co-author DOI 10.1586/era.13.28↗

Grants 7

  1. Protein Kinase D1 as a switch from acute to chronic pancreatitis R01DK139604↗
  2. Deiminated molecules as markers for developing pancreatic cancer - A1 R21CA279916↗
  3. Role of ICAM1 in development and progression of pancreatic cancer R01CA229560↗
  4. PKD1 signaling in the initiation of pancreatic cancer R01CA200572↗
  5. Smoking carcinogen-induced initiation of pancreatic cancer R21CA244167↗
  6. Protein Kinase D in oncogenic oxidative stress signaling R01CA140182↗
  7. Kinases Regulating Pancreatic Cancer Resistance to Chemotherapeutics AWARD pancan:2008-peter-storz-phd-kinases-regulating-pancreatic-cancer-res

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Heike R. Döppler · 9 shared papers, 2013–2025 · strength 1.77
  2. Alicia K. Fleming Martinez · 6 shared papers, 2022–2026 · strength 1.64
  3. Ligia I. Bastea · 6 shared papers, 2016–2025 · strength 1.10
  4. Veethika Pandey · 3 shared papers, 2019–2025 · strength 0.64
  5. Geou‐Yarh Liou · 6 shared papers, 2013–2022 · strength 0.62
  6. Howard C. Crawford · 2 shared papers, 2020 · strength 0.43
  7. Verline Justilien · 1 shared paper, 2026 · strength 0.28
  8. Nicole R Murray · 1 shared paper, 2026 · strength 0.28
  9. Dania S. Al-Qasrawi · 1 shared paper, 2026 · strength 0.28
  10. Michael B. Wallace · 1 shared paper, 2020 · strength 0.19
  11. E. Aubrey Thompson · 1 shared paper, 2024 · strength 0.18
  12. Lizhi Zhang · 1 shared paper, 2024 · strength 0.18
  13. Michael Anthony Hollingsworth · 1 shared paper, 2024 · strength 0.18
  14. Paul M. Grandgenett · 1 shared paper, 2024 · strength 0.18
  15. Nisha Durand · 1 shared paper, 2017 · strength 0.15
  16. Michael Leitges · 1 shared paper, 2016 · strength 0.10
  17. Marie C. Hasselluhn · 1 shared paper, 2016 · strength 0.06
  18. Jin‐San Zhang · 1 shared paper, 2016 · strength 0.06
  19. Elisabeth Heßmann · 1 shared paper, 2016 · strength 0.06
  20. Alexander Otto König · 1 shared paper, 2016 · strength 0.06
  21. Volker Ellenrieder · 1 shared paper, 2016 · strength 0.06
  22. Daniel D. Billadeau · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.